Synthesis method of sitagliptin intermediate
By using [Ru(COD)Cl2] and chiral bisphosphine ligand to perform asymmetric hydrogenation reaction under the action of acid, the problems of cumbersome operation, low yield and high cost in the preparation of sitagliptin intermediates are solved, and the problem of cumbersome operation, low yield and high cost are achieved. Highly efficient and low-cost high enantioselective preparation.
Patent Information
- Application Number
- CN202411221009.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-11-26
AI Technical Summary
The existing preparation method for sitagliptin intermediates has problems such as cumbersome operation, low yield, low enantioselectivity and high cost.
Asymmetric hydrogenation reaction of a metal catalyst [Ru(COD)Cl2] and chiral bisphosphine ligands such as (R,R,R,R,R)-BIBOP under the action of acids, through an α-chiral amine compound Synthesis method to achieve efficient preparation of sitagliptin intermediates.
The preparation of sitagliptin intermediates with high enantioselectivity and high yield is achieved, reducing costs and simplifying the operation process.
Smart Images

Figure CN119019274A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a method for preparing a sitagliptin intermediate. Background Art
[0002] Sitagliptin, (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine (Sitagliptin), is an oral antidiabetic drug that belongs to the class of dipeptidyl peptidase-4 (DPP-4 inhibitors). DPP-4 inhibitors are a class of drugs that indirectly regulate insulin secretion by inhibiting the degradation of glucagon-like peptide 1 (GLP-1) and are used to treat type 2 diabetes. Sitagliptin was developed by Merck in 2005 and was approved by the U.S. Food and Drug Administration (FDA) the following year. Due to its good safety and low incidence of adverse reactions, it has become the world's best-selling and most representative DPP-4 inhibitor, which can be used alone or in combination with other oral hypoglycemic drugs (such as metformin).
[0003] In 2021, there are 529 million diabetes patients worldwide (95% UI 5-564 million), of which 96.0% have type 2 diabetes. There are about 140 million diabetes patients in China. In 2023, the size of China's diabetes market reached 4.7 billion US dollars, and it is expected that the market size may reach 9.3 billion US dollars by 2032. The global annual sales of sitagliptin have remained above 4 billion US dollars in recent years. Before 2020, the production of sitagliptin APIs has been monopolized by the original developer Merck. Since 2020, many domestic pharmaceutical companies have approved the listing of sitagliptin generic drugs.
[0004] The structure of sitagliptin consists of a trifluorobenzene ring, a tetrahydrotriazole pyrazine nitrogen heterocycle and a four-carbon chain α-chiral amine. Since the synthesis methods of trifluorobenzene rings and tetrahydrotriazole pyrazine nitrogen heterocycles are relatively fixed and mature, the efficient construction of chiral amines has become the key to achieving cost reduction and efficiency improvement in the research of sitagliptin synthesis process. In the first sitagliptin synthesis route reported by Merck, chiral amines are synthesized by asymmetric hydrogenation of β-keto esters to chiral alcohols and then obtained through multi-step transformations. This synthesis route is relatively costly because it uses the Mitsunobu reaction with low atom economy and requires multi-step transformations.
[0005]
[0006] In 2009, Merck developed a second-generation synthesis process based on the asymmetric hydrogenation of enamine amides to construct α-chiral amines. Using [Rh(COD)Cl]2 and ferrocene-type ligand tBu-Josiphos as the catalytic system, high enantioselective hydrogenation of enamine amides was achieved, but the expensive rhodium catalyst is still the main cost of the process. In order to achieve a lower catalyst dosage, Professor Zhang Xumu's team developed rhodium-DuanPhos catalysis, which achieved efficient asymmetric hydrogenation of acetyl-protected enamine esters. The rhodium catalyst dosage was reduced to 0.02 mol%, but the acetyl protection of the hydrogenated substrate and the deprotection of the reduced product increased the cost of the method. Later, Merck reported the use of chiral ruthenium catalyst Ru(OAc)2[(R)-DM-SegPhos] to achieve asymmetric hydrogenation of enamine amides. Although the ruthenium catalyst is relatively cheap and the method shows high yield and high enantioselectivity, the high sensitivity of the reaction system to salt affects its practicality. Because the metal-catalyzed asymmetric hydrogenation method performed imperfectly, Merck subsequently developed a more economical and green biocatalytic strategy to prepare sitagliptin.
[0007] Summary of the invention
[0008] The technical problem to be solved by the present invention is to overcome the problems of complicated operation, low yield, low enantioselectivity and high cost in the existing sitagliptin intermediate preparation method, and to provide a new method for obtaining a sitagliptin intermediate by providing a low-cost and efficient α-chiral amine compound with high enantioselectivity.
[0009] The present invention solves the above-mentioned technical problems through the following technical solutions.
[0010] The present invention provides a method for synthesizing an α-chiral amine compound, which comprises the following steps: in an organic solvent, under the catalysis of a metal catalyst and a chiral diphosphine ligand, under the action of an acid, a compound as shown in formula I is subjected to an asymmetric hydrogenation reaction with hydrogen to obtain an α-chiral amine compound as shown in formula II,
[0011]
[0012] Where R is C 1-8 Alkyl, C 3-12 Cycloalkyl, C 6-10 The aryl group or heteroatom is selected from 1, 2 or 3 of N, O and S, and the number of heteroatoms is 1, 2 or 3 5-10 membered heteroaryl groups;
[0013] The metal catalyst is [Ru(COD)Cl2]2;
[0014] The chiral bisphosphine ligand is one or more of (R,R,R,R)-BIBOP, (R,R,R,R)-MeO-BIBOP, the compound represented by formula L1, and the compound represented by formula L2;
[0015]
[0016] The acid is one or more of benzenesulfonic acid, benzenesulfonic acid hydrate, p-toluenesulfonic acid and p-toluenesulfonic acid hydrate.
[0017] Preferably, R is C 1-8 Alkyl; for example, isopropyl.
[0018] The organic solvent may be an organic solvent commonly used in this type of reaction in the art. Preferably, the organic solvent is one or more of methanol, ethanol, dichloromethane and toluene, such as methanol and dichloromethane, wherein the volume ratio of methanol to dichloromethane may be 1:(1-3), such as 1:2.
[0019] The amount of the organic solvent used may be a conventional amount used in this type of reaction in the art. Preferably, the molar volume ratio of the compound as shown in Formula I to the organic solvent is (0.05-0.1) mol / L, for example, 0.07 mol / L.
[0020] The amount of the metal catalyst used may be the conventional amount used in such reactions in the art. Preferably, the molar ratio of the compound as shown in formula I to the metal catalyst may be 100:(0.1-3), for example, 100:0.5 or 100:2.5; more preferably, when the chiral bisphosphine ligand is (R,R,R,R)-BIBOP, the molar ratio of the compound as shown in formula I to the metal catalyst is 100:(0.1-1); when the chiral bisphosphine ligand is (R,R,R,R)-MeO-BIBOP, a compound as shown in formula L1 and / or a compound as shown in formula L2, the molar ratio of the compound as shown in formula 1 to the metal catalyst is 100:(2-3).
[0021] Preferably, the chiral bisphosphine ligand is (R,R,R,R)-BIBOP.
[0022] The amount of the chiral bisphosphine ligand used can be the conventional amount used in this type of reaction in the art. Preferably, the molar ratio of the compound as shown in formula I to the chiral bisphosphine ligand is 100:(0.5-10), for example, 100:1.2 or 100:6; more preferably, when the chiral bisphosphine ligand is (R,R,R,R)-BIBOP, the molar ratio of the compound as shown in formula I to the chiral bisphosphine ligand is 100:(1-1.5); when the chiral bisphosphine ligand is (R,R,R,R)-MeO-BIBOP, a compound as shown in formula L1 and / or a compound as shown in formula L2, the molar ratio of the compound as shown in formula I to the chiral bisphosphine ligand is 100:(5-7).
[0023] Preferably, the acid is p-toluenesulfonic acid monohydrate.
[0024] Preferably, the molar ratio of the acid to the compound of the structure shown in Formula I is (1-3):1, for example, the molar ratio of the acid to the compound of the structure shown in Formula I is 1:1 or 2.5:1; more preferably, the molar ratio of the acid to the compound of Formula I is 2.5:1.
[0025] Preferably, an ammonium salt is further added to the asymmetric hydrogenation reaction. More preferably, the ammonium salt is one or more of ammonium chloride, ammonium iodide, ammonium acetate, ammonium salicylate and ammonium p-toluenesulfonate, for example, ammonium p-toluenesulfonate.
[0026] Preferably, the molar ratio of the ammonium salt to the compound as shown in Formula I is (1-5):1, for example, 3:1.
[0027] The amount of hydrogen used can be the conventional amount used in this type of reaction in the art. Preferably, the hydrogen pressure is 1-100 atm, more preferably, the hydrogen pressure is 40-60 atm, for example, the hydrogen pressure is 50 atm.
[0028] Preferably, the reaction temperature of the asymmetric hydrogenation reaction is 25-80°C, such as 25°C, 40°C, 50°C or 60°C; more preferably, 55-65°C.
[0029] The progress of the asymmetric hydrogenation reaction can be monitored by conventional detection methods in the art (such as TLC, NMR, HPLC or GC). Generally, the disappearance of the starting material is taken as the end point of the reaction. Preferably, the reaction time of the asymmetric hydrogenation reaction is 6-32 h, such as 22 h or 24 h.
[0030] After the reaction is completed, a purification step is further included. The purification step is a conventional purification method for this type of compound in the art, such as column chromatography separation or preparative plate separation.
[0031] The positive and progressive effects of the present invention are:
[0032] The invention uses (Z)-3-amino-4-(2,4,5-trifluorophenyl)but-2-enoate as a starting material, adopts an asymmetric hydrogenation reaction strategy catalyzed by a transition metal and a chiral ligand, prepares an α-chiral amine compound from a simple and readily available enamine ester through a one-step reaction, and synthesizes a sitagliptin intermediate with high enantioselectivity.
[0033] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention. DETAILED DESCRIPTION
[0034] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0035] Example 1
[0036]
[0037] A stirring bar, compound 1 (27.3 mg, 0.1 mmol), TsOH·H2O (47.5 mg, 0.25 mmol), and NH4OTs (56.7 mg, 0.3 mmol) were added to a 4 mL vial and then moved to a glove box. A stirring bar, [Ru(cod)Cl2]2 (0.28 mg, 0.5 mol%), and (R,R,R,R)-BIBOP (0.46 mg, 1.2 mol %) were added to a 4 mL vial and dissolved in DCM (0.3 mL). The catalyst mixture was stirred in the glove box for 30 minutes and added to the substrate. The solvent DCM (0.7 mL) and MeOH (0.5 mL) were added and then transferred to an autoclave. The autoclave was replaced with H2 three times and filled with 50 atm H2. The autoclave was heated in a preheated 60°C oil bath for 22 hours.
[0038] After the reaction was completed, the autoclave was cooled to room temperature and carefully decompressed in a fume hood. 19 F NMR (fluorobenzene was added to the system as an internal standard) confirmed whether the reaction was complete. The crude product was purified by silica gel column chromatography (eluent: PE / EA = 7 / 1) to obtain the desired sitagliptin intermediate 2 (26.6 mg, 97% yield, 99% ee). 1H NMR (400MHz, Chloroform-d) δ 7.12 (ddd, J = 10.5, 8.8, 6.8 Hz, 1H), 6.90 (td, J=9.7,6.6 Hz, 1H), 5.05 (hept, J=6.3 Hz, 1H), 4.22 (dp, J=9.6, 3.1 Hz, 1H), 3.23 (d, J=3.9 Hz, 1H), 2.78 (d, J=6.3 Hz, 1H), 2.56–2.27 (m, 2H), 1.25 (d, J=6.2Hz, 6H). 19 F NMR (376 MHz, Chloroform-d) δ -119.28 (dd, J=15.2, 3.3 Hz), -135.95 (dd, J=21.7, 3.3 Hz), -143.08 (dd, J=21.5, 15.4 Hz). HRMS(ESI) calcd.for C13H17F3NO2 [M+H] + : m / z 276.1206; m / z found: 276.1210. The enantiomeric excess of compound 2 was determined by chiral HPLC analysis. HPLC detection conditions: chiral IC column; column temperature 25℃; mobile phase is isopropanol:n-hexane = 10:90; flow rate 0.8 mL / min; detection wavelength n = 254nm; retention time t1 = 7.4 min, t2 = 7.9 min.
[0039] Example 2
[0040] The ruthenium-catalyzed asymmetric hydrogenation of β-2,4,5-trifluorophenyl β-enamino ester (1) was investigated. The reaction was carried out under the conditions of [Ru(COD)Cl2]2 (2.5 mol %) / (R,R,R,R)-BIBOP (6 mol %) as the catalyst system and TsOH·H2O (1 equiv) as the additive. The reaction was carried out under the conditions of 50 atm H2 pressure, 25℃ reaction temperature, DCM / MeOH (2 / 1, v / v) as the reaction solvent, and 24 hours of reaction. The substrate 1 was completely converted, and the obtained hydrogenation product 3-amino-4-(2,3,5-trifluorophenyl)butyric acid isopropyl ester (2) had an optical purity of 99% ee, but the yield was low (13%) (Table 1, entry 1). The low yield of the reaction was due to the Michael addition reaction between the hydrogenation product and the substrate to form a dimer byproduct 3. If there is no ruthenium catalyst precursor or chiral phosphine ligand in the catalytic system, the hydrogenation reaction cannot occur (entries 2-3). Equivalent acid additives are also indispensable for this asymmetric hydrogenation reaction. If no acid is added to the system, the hydrogenation product 2 cannot be obtained (entry 4). Then we also screened different metal precursors, [Rh(COD)Cl]2, [Ir(COD)Cl2]2, [Ru(COD)(CF3COO)2] and [Ru(COD)(2-methylallyl)2]2 all showed catalytic activity comparable to [Ru(COD)Cl2]2, but the ee value of the hydrogenation product was lower (entries 5-8). The neutral [Ru(COD)Cl2]2 showed better enantioselectivity than [Ru(COD)(CF3COO)2] and [Ru(COD)(2-methylallyl)2]2.
[0041]
[0042] Table 1 Reaction conditions screening
[0043]
[0044] a Standard reaction conditions: 1 (0.1 mmol), [M]=[Ru(COD)Cl2]2 (2.5 mol%), Ligand=(R,R,R,R)-BIBOP (6 mol%), TsOH·H2O (0.1 mmol), DCM / MeOH (2 / 1, 1.5 mL), H2 (50atm), 25℃, 24 h.). b The reaction conversion and yield are given by 19 In F NMR measurement, fluorobenzene was added into the system as an internal standard. c The ee value of the product was determined by chiral HPLC.
[0045] Example 3
[0046] Different chiral bisphosphine ligands including a series of chiral bisphosphine ligands with 2,3-dihydrobenzo[d][1,3]phosphinodihydrofuran skeleton and commercial ligands with chiral biaryl skeleton were also applied to the reaction. More chiral bisphosphine ligands showed good stereoselectivity including (R,R,R,R)-BIBOP (99% ee), (R,R,R,R)-MeO-BIBOP (97% ee), L1 (96% ee), L2 (97% ee), (S)-BINAP (89% ee) and (S)-GarPhos (90% ee). Other BIBOP-type ligands such as (R,R,R,R)-Ph-BIBOP, (R,R,R,R)-DI-BIDIME, L3, (R,R,R,R)-WingPhos, (R,R)-BABIBOP, etc., gave almost racemic products or no products, proving the significant effect of the change of substituents in the ligand structure on stereoselectivity and activity. Since the dimerization byproduct 3 was generated to varying degrees in all the converted asymmetric hydrogenation reactions, the yields were not perfect. The formation of the dimerization byproduct 3 can be effectively controlled by changing the reaction conditions. For example, when (R,R,R,R)-BIBOP was used as a ligand, the reaction temperature was changed from room temperature to 40°C, and the yield increased from 13% to 25%; changing the amount of ruthenium catalyst also achieved a change in yield. For example, when (R,R,R,R)-MeO-BIBOP was used as a ligand and the reaction temperature was changed from room temperature to 40°C, the yield increased from 55% to 91%, while reducing the amount of ruthenium catalyst also led to a significant decrease in the yield. These experimental phenomena indicate that high yields can be achieved by optimizing reaction conditions, and stereoselectivity is mainly determined by different chiral bisphosphine ligands.
[0047] Screening of chiral bisphosphine ligands
[0048]
[0049] a Unless otherwise specified, the reactions were carried out under the following conditions: 1 (0.1 mmol), [Ru(COD)Cl2]2 (2.5 mol%), (R,R,R,R)-BIBOP (6 mol%), TsOH·H2O (0.1 mmol), DCM / MeOH (2 / 1, 1.5 mL), H2 (50 atm), 25°C, 24 h.). The reaction conversion and yield were given by 19 F NMR was used to determine the product, with fluorobenzene added as an internal standard. The ee value of the product was determined by chiral HPLC. b T = 40 °C.c [Ru(COD)Cl2]2 (0.5 mol%), ligand (1.2 mol%), T = 40 ℃.
[0050] Example 4
[0051] Adding an equivalent amount of acid can promote the formation of salts of amine products, thereby reducing the nucleophilicity of amine products and reducing the production of dimerization byproduct 3. The effect of acid as an additive on the reaction is shown in Table 2. The type of acid affects not only the reaction activity but also the enantioselectivity of asymmetric hydrogenation. The introduction of acetic acid did not achieve the formation of product 2 (entry 1), while citric acid as an additive led to a significant decrease in enantioselectivity (entry 2). Benzenesulfonic acid and p-chlorobenzenesulfonic acid showed good enantioselectivity, but were slightly inferior to p-toluenesulfonic acid (entries 3-4). 1-Naphthol-5-sulfonic acid and 4-methyl-N-[(4-methylphenyl)sulfonyl]benzenesulfonamide could not promote the formation of 2 (entries 5-6). The equivalent of acid was further optimized (entries 7-16). When 2.5 equivalents of p-toluenesulfonic acid were added to the system, enamine 1 was completely converted and the NMR yield of product 2 was 80% (entry 13). When the amount of acid added exceeded 2.5 equivalents, more by-products were generated in the system and the yield of product 2 gradually decreased.
[0052]
[0053] Table 2 Condition screening
[0054]
[0055] a Unless otherwise stated, the reactions were carried out under the following conditions: 1 (0.1 mmol), [Ru(COD)Cl2]2 (2.5 mol%), (R,R,R,R)-BIBOP (6 mol%), acid (0.1 mmol), DCM / MeOH (2 / 1, 1.5 mL), H2 (50 atm), 25°C, 24 h.). b The reaction conversion and yield are given by 19 In F NMR measurement, fluorobenzene was added into the system as an internal standard. c The ee value of the product was determined by chiral HPLC.
[0056] Example 5
[0057] The effect of ammonium p-toluenesulfonate as an additive on the reaction was investigated (Table 3). When 3 equivalents of ammonium p-toluenesulfonate were added to the reaction system, the reaction yield did not increase at a reaction temperature of 40°C, and remained at 80% (entry 1). When the reaction temperature was increased to 50°C, the reaction yield increased to 89% (entry 2). When the reaction temperature was increased to 60°C,19 F NMR monitoring showed that the reaction system contained entirely product 2, with a NMR yield of 97% and an enantioselectivity of 99% ee.
[0058]
[0059] Table 3 Investigation of ammonium p-toluenesulfonate
[0060]
[0061] a Unless otherwise stated, the reactions were carried out under the following conditions: 1 (0.1 mmol), [Ru(COD)Cl2]2 (2.5 mol%), (R,R,R,R)-BIBOP (6 mol%), TsOH·H2O (0.25 mmol), NH4OTs (0.3 mmol), DCM / MeOH (2 / 1, 1.5 mL), H2 (50 atm), 25°C, 24 h.). b The reaction conversion and yield are given by 19 In F NMR measurement, fluorobenzene was added into the system as an internal standard. c The ee value of the product was determined by chiral HPLC.
Claims
1. A method for synthesizing an α-chiral amine compound, characterized in that: It includes the following steps: In an organic solvent, under the catalysis of a metal catalyst and a chiral diphosphine ligand, under the action of an acid, the compound shown in formula I undergoes an asymmetric hydrogenation reaction with hydrogen to obtain an α-chiral amine compound shown in formula II. ; Where R is C 1-8 Alkyl, C 3-12 Cycloalkyl, C 6-10 The aryl group or heteroatom is selected from 1, 2 or 3 of N, O and S, and the number of heteroatoms is 1, 2 or 3 5-10 membered heteroaryl groups; The metal catalyst is [Ru(COD)Cl2]2; The chiral bisphosphine ligand is one or more of (R,R,R,R)-BIBOP, (R,R,R,R)-MeO-BIBOP, the compound represented by formula L1, and the compound represented by formula L2; ; The acid is one or more of benzenesulfonic acid, benzenesulfonic acid hydrate, p-toluenesulfonic acid and p-toluenesulfonic acid hydrate.
2. The synthesis method according to claim 1, characterized in that It meets one or more of the following conditions: (1) The molar ratio of the compound of formula I to the metal catalyst is 100:(0.1-3); (2) The chiral diphosphine ligand is (R,R,R,R)-BIBOP; (3) The molar ratio of the compound of formula I to the chiral bisphosphine ligand is 100:(0.5-10); (4) the acid is p-toluenesulfonic acid monohydrate; and (5) The molar ratio of the acid to the compound having the structure shown in Formula I is (1-3):
1.
3. The synthesis method according to claim 1, characterized in that It meets one or more of the following conditions: (1) When the chiral bisphosphine ligand is (R,R,R,R)-BIBOP, the molar ratio of the compound of formula I to the metal catalyst is 100:(0.1-1); when the chiral bisphosphine ligand is (R,R,R,R)-MeO-BIBOP, the compound of formula L1 and / or the compound of formula L2, the molar ratio of the compound of formula I to the metal catalyst is 100:(2-3); and (2) When the chiral bisphosphine ligand is (R,R,R,R)-BIBOP, the molar ratio of the compound as shown in formula I to the chiral bisphosphine ligand is 100:(1-1.5); when the chiral bisphosphine ligand is (R,R,R,R)-MeO-BIBOP, the compound as shown in formula L1 and / or the compound as shown in formula L2, the molar ratio of the compound as shown in formula I to the chiral bisphosphine ligand is 100:(5-7).
4. The synthesis method according to claim 1, characterized in that It meets one or more of the following conditions: (1) The molar ratio of the compound of formula I to the metal catalyst is 100:0.5 or 100:2.5; (2) The molar ratio of the compound of formula I to the chiral bisphosphine ligand is 100:1.2 or 100:6; and (3) The molar ratio of the acid to the compound of formula I is 1:1 or 2.5:1; for example, the molar ratio of the acid to the compound of formula I is 2.5:
1.
5. The synthesis method according to claim 1, characterized in that It meets one or more of the following conditions: (1) R is C 1-8 alkyl; (2) The organic solvent is one or more of methanol, ethanol, dichloromethane and toluene; (3) The molar volume ratio of the compound represented by formula I to the organic solvent is (0.05-0.1) mol / L; (4) The hydrogen pressure is 1-100 atm; (5) The reaction temperature of the asymmetric hydrogenation reaction is 25-80 °C; (6) The reaction time of the asymmetric hydrogenation reaction is 6-32h; and (7) After the reaction is completed, the method further comprises a purification step, wherein the purification step is a column chromatography separation method or a preparative plate separation method.
6. The synthesis method according to claim 1, characterized in that It meets one or more of the following conditions: (1) R is isopropyl; (2) The organic solvent is methanol and dichloromethane, wherein the volume ratio of methanol to dichloromethane is 1:(1-3); (3) the hydrogen pressure is 40-60 atm; and (4) The reaction temperature of the asymmetric hydrogenation reaction is 55-65°C.
7. The synthesis method according to claim 1, characterized in that It meets one or more of the following conditions: (1) The molar volume ratio of the compound represented by Formula I to the organic solvent is 0.07 mol / L; (2) The organic solvent is methanol and dichloromethane, wherein the volume ratio of methanol to dichloromethane is 1:2; (3) The hydrogen pressure is 50 atm; (4) the reaction temperature of the asymmetric hydrogenation reaction is 25°C, 40°C, 50°C or 60°C; and (5) The reaction time of the asymmetric hydrogenation reaction is 22 h or 24 h.
8. The synthesis method according to claim 1, characterized in that The asymmetric hydrogenation reaction also adds an ammonium salt.
9. The synthesis method according to claim 8, characterized in that It meets one or more of the following conditions: (1) The ammonium salt is one or more of ammonium chloride, ammonium iodide, ammonium acetate, ammonium salicylate and ammonium p-toluenesulfonate; and (2) The molar ratio of the ammonium salt to the compound shown in Formula I is (1-5):
1.
10. The synthesis method according to claim 8, characterized in that It meets one or more of the following conditions: (1) the ammonium salt is ammonium p-toluenesulfonate; and (2) The molar ratio of the ammonium salt to the compound of formula I is 3:1.
Citation Information
Cited By
Method for synthesizing sitagliptin through cobalt-catalyzed asymmetric hydrogenation
CN120463714A
